不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
鼻型结外 NK/T 细胞淋巴瘤患者进行中期 (18)F-FDG PET/CT 检查的适当时机
英文原题：Appropriate timing to perform an interim (18)F-FDG PET/CT in patients with nasal-type extranodal natural killer/T cell lymphoma.
查看英文原题
Appropriate timing to perform an interim (18)F-FDG PET/CT in patients with nasal-type extranodal natural killer/T cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
interim 18 F-FDG PET/CT（I-PET）在鼻型结外自然杀伤/T细胞淋巴瘤（ENKTL）患者的疗效评估和治疗指导中具有一定作用。
然而，对于I-PET的进行时机——是在化疗后还是放化疗后——尚未达成一致。我们旨在通过评估I-PET在ENKTL患者疗效评估中的预后价值，来寻找I-PET的适当时机。回顾性纳入227例接受过I-PET的ENKTL患者。所有患者根据所接受的治疗策略分为化疗组或放化疗组。采用Deauville 5分评分（DS）判读I-PET图像。使用风险比（HR）和C-index衡量不同时间进行I-PET的区分能力和预后评估能力。106例患者在化疗后接受I-PET（化疗组），而121例患者在放化疗后接受I-PET（放化疗组）。根据Deauville标准，87例患者被归类为代谢缓解（DS评分1-3），其余140例被归类为非代谢缓解（DS评分4-5）。
在代谢缓解与非代谢缓解患者之间，无进展生存期（PFS，p = 0.406）或总生存期（OS，p = 0.350）均无显著生存差异。在化疗组中，代谢缓解患者的PFS显著优于非代谢缓解患者（p = 0.012）。对于OS，生存曲线在代谢缓解与非代谢缓解患者之间也呈现出区分趋势（p = 0.082）。在放化疗组中，代谢缓解与未代谢缓解的患者在PFS（P = 0.185）或OS（P = 0.627）方面无显著差异。化疗后I-PET具有更高的区分能力，并能够对鼻型ENKTL患者进行预后预测。放化疗后I-PET无预后价值。
因此，对于鼻型ENKTL患者的疗效评估，I-PET的适当时机是化疗后、放疗前。
展开英文摘要原文
Interim 18 F-FDG PET/CT (I-PET) has a role in response evaluation and treatment guidance in patients with nasal-type extranodal natural killer/T cell lymphoma (ENKTL).
However, there was no agreement on the timing of I-PET performed, after chemotherapy or after chemoradiotherapy.
We aimed to find the appropriate timing for I-PET by assessing the prognostic value of I-PET in response evaluation in ENKTL patients. Two hundred and twenty-seven ENKTL patients who had undergone I-PET were retrospectively included. All patients were grouped based on their therapeutic strategy received, chemotherapy or chemoradiotherapy. The Deauville 5-point score (DS) was used to interpret the I-PET images. The hazard ratio (HR) and C-index were used to measure the discriminatory and prognostic capacities of I-PET performed at different times. One hundred and six patients underwent the I-PET after chemotherapy (chemotherapy group), while I-PET was performed after chemoradiotherapy in 121 patients (chemoradiotherapy group). Eighty-seven patients were classified as metabolic remission (DS score of 1-3), while the other 140 were classified as non-metabolic remission (DS score of 4-5) according to the Deauville criteria.
There were no significant survival differences between patients in metabolic remission and in non-metabolic remission in either progression-free survival (PFS, p = 0. 406) or overall survival (OS, p = 0. 350). In the chemotherapy group, patients in metabolic remission had significantly superior PFS than patients in non-metabolic remission (p = 0. 012). For OS, a discriminative trend was also found on the survival curve between patients in metabolic remission and in non-metabolic remission (p = 0.
082). In the chemoradiotherapy group, there was no significant difference in PFS (P = 0. 185) or OS (P = 0. 627) between patients in metabolic remission and in non-metabolic remission. I-PET after chemotherapy yields higher discriminative power and has the ability for prognostic prediction in nasal-type ENKTL patients. I-PET after radiochemotherapy has no prognostic value.
Thus, the appropriate timing for I-PET is after chemotherapy but before radiotherapy for response evaluation in nasal-type ENKTL patients.
论文信息
- 作者
- Wang R、Zhang Y、Fan Q、Jiang M、Zou L、Su M
- 第一作者单位
- Department of Nuclear Medicine, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu, 610041, Sichuan, China.China
- 通讯作者单位
- Department of Nuclear Medicine, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu, 610041, Sichuan, China. suminggang@sina.com.China
- 期刊
- Annals of hematology2024 Mar
- 原文标识
- PubMed 38030892 · DOI 10.1007/s00277-023-05562-2